For Eniola Olutogun, the strongest angle is to position the venture as a computational biotech startup that, while primarily in silico, requires wet lab validation of predicted resistance mutations. Emphasize the need for affordable lab space to conduct validation experiments, and highlight the venture's alignment with Open Cell's mission to support early-stage life science innovation. The venture's focus on drug resistance mutations directly addresses a critical unmet need in drug discovery, making it a compelling candidate for Open Cell's community.

The venture is not yet incorporated, which may be a concern for an incubator that likely expects a legal entity. Additionally, the programme's focus on wet lab space may be less critical for a purely computational venture, though validation experiments could justify the need.